www.tesseratherapeutics.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $558.91MM
Tessera Therapeutics is developing a genome engineering technology, Gene Writing™. The goal of Gene Writing™ is to be able to make genomic alterations that can be used to treat or cure disease. Tessera Therapeutics was founded in 2018 by Geoffrey von Maltzahn Ph.D., Jacob Rubens, Ph.D., and Noubar Afeyan, Ph.D. and is headquartered in Cambridge, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/19/2022 | Series C | $300MM | $xx.xx | $1.77B | Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Artis Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, Salt Fund, Softbank, T. Rowe Price | |
Price per Share
$xx.xx
Shares Outstanding
14,669,927
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Artis Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, Salt Fund, Softbank, T. Rowe Price
|
||||||
01/12/2021 | Series B | $232.5MM | $xx.xx | $760.65MM | Alaska Permanent Fund, Altitude Life Science Ventures, Qatar Investment Authority, Softbank | |
Price per Share
$xx.xx
Shares Outstanding
19,804,092
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alaska Permanent Fund, Altitude Life Science Ventures, Qatar Investment Authority, Softbank
|
||||||
07/07/2020 | Series A-2 | $5MM | $xx.xx | $66.08MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
2,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|
||||||
07/07/2020 | Series A-1 | $6.6MM | $xx.xx | $66.08MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
3,298,161
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|
||||||
07/07/2020 | Series A | $14.81MM | $xx.xx | $66.08MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
14,809,929
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|